Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study

G. Cabibbo, S. Petta, V. Calvaruso, I. Cacciola, M. R. Cannavò, S. Madonia, M. Distefano, Maria Grazia Distefano, L. Larocca, Luigi Maria Larocca, T. Prestileo, F. Tinè, G. Bertino, L. Giannitrapani, F. Benanti, A. Licata, Maria Angela Vittoria Anna Chiara Licata, I. Scalisi, G. Mazzola, F. CartabellottaN. Alessi, M. Barbàra, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, A. Craxì, V. Di Marco, C. Cammà, V. Di Marco, C. Cammà, V. Calvaruso, S. Petta, P. Colletti, G. Mazzola, L. Giannitrapani, S. Corrao, T. Prestileo, F. Di Lorenzo, R. Fecarotta, P. Sanfilippo, S. Madonia, F. Tinè, G. Malizia, F. Latteri, M. Maida, F. Cartabellotta, R. Vassallo, I. Cacciola, G. Caccamo, S. Maimone, C. Saitta, G. Squadrito, L. Mondello, A. Smedile, A. L. Ardiri, A. Montineri, L. N. Larocca, Beatrice Marina Cacopardo, B. Cacopardo, F. Benanti, M. Russello, R. Benigno, M. R. Cannavò, A. Bellia, C. Iacobello, A. Davì, M. A. Di Rosolini, A. Digiacomo, G. Fuduli, G. Scifo, Maria Grazia Distefano, M. Distefano, V. Portelli, F. Savalli, I. Scalici, G. Gioia, A. Magro, G. Alaimo, A. Salvo, A. Averna, F. Lomonaco, U. Quattrocchi, L. Guarneri, F. Maffeo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

87 Citazioni (Scopus)


Background: Data on HCV-related hepatocellular carcinoma (HCC) early recurrence in patients whose HCC was previously cured, and subsequently treated by direct-acting antivirals (DAAs), are equivocal. Aim: To assess the risk of HCC early recurrence after DAAs exposure in a large prospective cohort of HCV-cirrhotic patients with previous successfully treated HCC, also looking for risk factors for cancer early recurrence. Methods: We enrolled 143 consecutive patients with complete response after curative treatment of HCC, subsequently treated with DAAs and monitored by the web-based RESIST-HCV database. Clinical, biological, and virological data were collected. The primary endpoint was the probability of HCC early recurrence from DAA starting by Kaplan-Meier method. Results: Eighty-six per cent of patients were in Child-Pugh class A and 76% of patients were BCLC A. Almost all patients (96%) achieved sustained virological response. Twenty-four HCC recurrences were observed, with nodular or infiltrative pattern in 83% and 17% of patients, respectively. The 6-, 12- and 18-month HCC recurrence rates were 12%, 26.6% and 29.1%, respectively. Main tumour size and history of prior HCC recurrence were independent risk factors for HCC recurrence by Cox multivariate model. Conclusions: Probability of HCC early recurrence in patients who had HCC previously cured remains high, despite HCV eradication by DAAs. Risk was comparable but not higher to that reported in literature in DAA-untreated patients. Previous HCC recurrence and tumour size can be used to stratify the risk of HCC early recurrence. Further studies are needed to assess impact of DAAs on late recurrence and mortality.
Lingua originaleEnglish
pagine (da-a)688-695
Numero di pagine8
Stato di pubblicazionePubblicato - 2017


  • Aged
  • Antiviral Agents
  • Carcinoma, Hepatocellular
  • Catheter Ablation
  • Female
  • Hepatitis C
  • Humans
  • Liver Cirrhosis
  • Liver Neoplasms
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Prospective Studies
  • Risk Factors


Entra nei temi di ricerca di 'Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study'. Insieme formano una fingerprint unica.

Cita questo